Skip to content

Study · Randomized controlled trial · n = 202 · 2017

6 results

GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial.

Leonard RCF, Adamson DJA, Bertelli G, Mansi J, Yellowlees A, Dunlop J, Thomas GA, Coleman RE, Anderson RA

Annals of oncology : official journal of the European Society for Medical Oncology1 Aug 2017Cited by 119 (Europe PMC)

PMID28472240 (opens in a new tab)DOI10.1093/annonc/mdx184 (opens in a new tab)PepBankPUB-28472240
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women receiving breast cancer chemotherapy, goserelin reduced amenorrhoea to 22% versus 38% in controls between 12 and 24 months (P = 0.015).

    In plain wordsIn women receiving breast cancer chemotherapy, goserelin reduced absent periods compared with controls.

    Peptide
    Goserelin
    Outcome
    DecreaseAmenorrhoea between 12 and 24 months
    Study

    n = 202

    Comparator
    Control chemotherapy group
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Amenorrhoea
    22%
    goserelin
    Amenorrhoea
    38%
    control

    Source sentences

    Summary
    Goserelin reduced the prevalence of amenorrhoea between 12 and 24 months to 22% versus 38% in the control group (P = 0.015) and the prevalence of POI to 18.5% versus 34.8% in the control group (P = 0.048).
    1 context sentence
    Summary · context
    This was a prospective, randomized, parallel group study of the gonadotropin-releasing hormone agonist goserelin administered before and during chemotherapy for breast cancer with stage I-IIIB disease.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women receiving breast cancer chemotherapy, goserelin reduced premature ovarian insufficiency to 18.5% versus 34.8% in controls (P = 0.048).

    In plain wordsIn women receiving breast cancer chemotherapy, goserelin reduced premature ovarian insufficiency compared with controls.

    Peptide
    Goserelin
    Outcome
    DecreasePremature ovarian insufficiency
    Study

    n: not reported in source

    Comparator
    Control chemotherapy group
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Premature ovarian insufficiency
    18.5%
    goserelin
    Premature ovarian insufficiency
    34.8%
    control

    Source sentences

    Summary
    Goserelin reduced the prevalence of amenorrhoea between 12 and 24 months to 22% versus 38% in the control group (P = 0.015) and the prevalence of POI to 18.5% versus 34.8% in the control group (P = 0.048).
    1 context sentence
    Summary · context
    This was a prospective, randomized, parallel group study of the gonadotropin-releasing hormone agonist goserelin administered before and during chemotherapy for breast cancer with stage I-IIIB disease.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women receiving breast cancer chemotherapy, goserelin lowered follicle stimulating hormone at 12 months versus controls (P = 0.027).

    In plain wordsIn women receiving breast cancer chemotherapy, goserelin lowered follicle stimulating hormone at 12 months compared with controls.

    Peptide
    Goserelin
    Outcome
    DecreaseFSH at 12 months
    Study

    n: not reported in source

    Comparator
    Control chemotherapy group
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    P value (FSH, goserelin versus control)
    0.027
    12 months

    Source sentences

    Summary
    Follicle stimulating hormone concentrations were also lower in all women treated with goserelin at both 12 and 24 months (P = 0.027, P = 0.001, respectively).
    1 context sentence
    Summary · context
    This was a prospective, randomized, parallel group study of the gonadotropin-releasing hormone agonist goserelin administered before and during chemotherapy for breast cancer with stage I-IIIB disease.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women receiving breast cancer chemotherapy, goserelin lowered follicle stimulating hormone at 24 months versus controls (P = 0.001).

    In plain wordsIn women receiving breast cancer chemotherapy, goserelin lowered follicle stimulating hormone at 24 months compared with controls.

    Peptide
    Goserelin
    Outcome
    DecreaseFSH at 24 months
    Study

    n: not reported in source

    Comparator
    Control chemotherapy group
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    P value (FSH, goserelin versus control)
    0.001
    24 months

    Source sentences

    Summary
    Follicle stimulating hormone concentrations were also lower in all women treated with goserelin at both 12 and 24 months (P = 0.027, P = 0.001, respectively).
    1 context sentence
    Summary · context
    This was a prospective, randomized, parallel group study of the gonadotropin-releasing hormone agonist goserelin administered before and during chemotherapy for breast cancer with stage I-IIIB disease.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women over 40 years receiving breast cancer chemotherapy, goserelin's effect was not statistically significant versus controls.

    In plain wordsIn women over 40 receiving breast cancer chemotherapy, goserelin's effect was not statistically significant compared with controls.

    Peptide
    Goserelin
    Outcome
    No significant changeOvarian protection in women over 40 years
    Study

    n: not reported in source

    Comparator
    Control chemotherapy group
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The effect of goserelin was not statistically significant in women >40 years.
    1 context sentence
    Summary · context
    This was a prospective, randomized, parallel group study of the gonadotropin-releasing hormone agonist goserelin administered before and during chemotherapy for breast cancer with stage I-IIIB disease.
  6. 06HumanRandomized controlled trialEfficacy outcome

    During breast cancer chemotherapy, median anti-Müllerian hormone fell to 7% of pretreatment levels with goserelin versus 5% in controls, without significant between-group difference.

    In plain wordsIn women receiving chemotherapy, ovarian reserve hormone fell in both groups, with no significant difference between goserelin and controls.

    Peptide
    Goserelin
    Outcome
    No significant changeAnti-Müllerian hormone ovarian reserve
    Study

    n: not reported in source

    Comparator
    Control chemotherapy group
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Median anti-Müllerian hormone
    7 % of pretreatment
    goserelin
    Median anti-Müllerian hormone
    5 % of pretreatment
    control

    Source sentences

    Summary
    Assessment of the ovarian reserve using anti-Müllerian hormone showed a marked fall in both groups during treatment to median values of 5% of pretreatment levels in the control group and 7% in the goserelin group, which were not significantly different between groups.
    1 context sentence
    Summary · context
    This was a prospective, randomized, parallel group study of the gonadotropin-releasing hormone agonist goserelin administered before and during chemotherapy for breast cancer with stage I-IIIB disease.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.